Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: In vivo gene therapies
Company stage: Pre-clinical
Diseases: Ocular diseases, haemoglobinopathies and immunooncology
Genome editing tool: CRISPR (undisclosed type)
Funding stage: Private
Location: San Francisco Bay Area, CA, USA
Spotlight Therapeutics is an early stage pre-clinical gene-editing company. Spotlight is focused on developing first-in-class in vivo gene-editing therapeutics. To do this it uses its proprietary technology platform Targeted Active Gene Editors (TAGE). The TAGE platform allows the company to address both delivery and in vivo CRISPR editing shortcomings.